P

    Painreform Ltd (PRFX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.95
    -0.01 (-0.78%)

    Market Cap: $2.92M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(13/20)
    Avg Surprise
    +3.76%
    Streak
    2 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$N/AN/AN/ABeat-
    Mar 26
    		$N/AN/AN/ABeat-
    Sep 25
    		$0.00$0.00N/ABeat+100.0%
    Jun 25
    		$-1.09$0.00N/AMiss+97.7%
    Mar 25
    		$-2.32N/A+69.79%Beat+99.3%
    Dec 24
    		$-2.32N/A+69.79%Beat+25.4%
    Sep 24
    		$-18.96$-4.74-300.00%Miss-132.9%
    Jun 24
    		$-48.00N/A+61.54%Beat+79.2%
    Mar 24
    		$-326.40$-288.00-13.33%Miss-148263.6%
    Dec 23
    		$-3.11$-1.49-108.72%Miss+99.1%
    Sep 23
    		$57.60N/A+134.29%Beat+124.0%
    Jun 23
    		$-230.40$-300.00+23.20%Beat-12.9%
    Mar 23
    		$-0.22$-0.32+31.25%Beat+99.9%
    Dec 22
    		$-348.00$-180.00-93.33%Miss-204605.9%
    Sep 22
    		$-240.00$-204.00-17.65%Miss-11.1%
    Jun 22
    		$-204.00$-192.00-6.25%Miss-6.3%
    Mar 22
    		$-192.00N/A+71.43%Beat+30.4%
    Dec 21
    		$-0.17N/A+69.09%Beat-
    Sep 21
    		$-216.00N/A+58.14%Beat-79900.0%
    Jun 21
    		$-192.00N/A+68.63%Beat+52.9%
    Mar 21
    		$-276.00N/A+58.93%Beat-131328.6%
    Dec 20
    		$0.00N/A+100.00%Beat+100.0%
    Sep 20
    		$-0.27N/A+98.33%Beat+78.3%
    Jun 20
    		$-408.00$-102.00-300.00%Miss-32708.0%
    Mar 20
    		$-0.21$0.00N/AMiss+75.2%
    Dec 19
    		$-0.10$0.00N/AMiss+88.2%
    Sep 19
    		$-1.24$0.00N/AMiss-51.1%
    Jun 19
    		$-1.24$0.00N/AMiss-51.1%
    Mar 19
    		$-0.85$0.00N/AMiss-5.4%
    Dec 18
    		$-0.85$0.00N/AMiss-5.4%
    Sep 18
    		$-0.82$0.00N/AMiss-
    Jun 18
    		$-0.82$0.00N/AMiss-
    Mar 18
    		$-0.80$0.00N/AMiss-
    Dec 17
    		$-0.80$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.01EV/EBITDA-2.32x
    Price/FCF-0.08xFCF Yield-1282.56%
    Profitability
    Profit Margin0.00%Operating Margin-16200.00%
    ROE-90.40%ROIC-185.01%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio1.78xQuick Ratio1.78x
    Trading Statistics
    Beta1.04Avg Volume366.85K
    52-Week High$9.0052-Week Low$0.91

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.98
    SMA 20$1.03
    SMA 50$1.17
    SMA 200$2.58
    EMA 10$0.99
    EMA 20$1.03
    EMA 50$1.21
    EMA 200$2.92

    MACD

    Line: -0.06Signal: -0.07Hist: 0.01

    ADX

    ADX: 33.6+DI: 27.5-DI: 16.3

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down68.0
    PSAR$1.03

    Bollinger Bands

    Upper Band$1.16
    Lower Band$0.90
    %B Position2596%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    40.7

    Momentum Oscillators

    Stoch %K19.2
    Stoch %D22.3
    Williams %R-85.6
    ROC (10d)-1.7%
    Momentum-0.02
    CCI (20d)-85.9
    MFI (14d)88.3

    Volatility Measures

    ATR (14d)$0.10(10.2%)
    StdDev (20d)0.07
    Hist Vol106.5%(High)

    Volume Flow

    VWAP$0.96
    OBV437.4M
    AD Line11.5B
    CMF (20d)0.695

    Volume Metrics

    Avg Vol (20d)380.7K
    Vol Ratio0.1x(Low)
    VWMA (20d)$1.15

    Pivot Points

    R3$1.08
    R2$1.05
    R1$1.00
    Pivot Point$0.97
    S1$0.93
    S2$0.90
    S3$0.86

    Advanced Oscillators

    TSI-15.53
    Ultimate Osc40.2
    KST-136.86

    Financial Data

    QuarterDec 2025Sep 2025Mar 2025Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Total Revenue$17,000$8,500N/AN/A$0$0$0$0$0$0$86,000$0
    Cost of Revenue$70,000$35,000N/AN/A$4,000$4,000$6,000$3,000$4,000$2,000$6,000$7,000
    Gross Profit$-53,000$-26,500N/AN/A$-4,000$-4,000$-6,000$-3,000$-4,000$-2,000$80,000$-7,000
    Operating Expenses$5.07M$1.35M$1.18M$881,500$7.34M$5.56M$3.56M$1.35M$2.25M$2.42M$3.26M$2.10M
    R&D$1.14M$429,000$139,000$149,000$6.67M$4.74M$2.75M$589,000$1.25M$1.45M$1.95M$1.05M
    SG&A$3.01M$547,000$958,500$732,500$680,000$823,000$818,000$763,000$1.01M$962,000$1.31M$1.05M
    Operating Income$-5,122,000$-1,377,000$-1,184,000$-881,500$-7,345,000$-5,565,000$-3,564,000$-1,352,000$-2,252,000$-2,416,000$-3,256,000$-2,096,000
    Interest Income$0$0$0$0$34,000$64,000$101,000$115,000$81,000$109,000$95,000$0
    Interest Expense$0$0$0$0$4,000$5,000$3,000$5,000$4,000$4,000$4,000$2,000
    Income Before Tax$-5,014,000$-1,349,000$-1,158,000$-881,000$-7,312,000$-5,506,000$-4,883,000$36,000$-2,181,000$-2,308,000$-3,157,000$-2,109,000
    Income Tax Expense$8,000$4,000$4,000$4,000$-1$0$8,000$-1,388,000$-71,000$-111,000$12,000$13,000
    Net Income$-4,838,000$-1,261,000$-1,158,000$-885,000$-7,312,000$-5,506,000$-4,891,000$36,000$-2,181,000$-2,197,000$-3,145,000$-2,122,000
    EBITDA$-4,240,000$-1,081,000$-1,093,000$-877,500$-7,341,000$-5,561,000$-3,558,000$-1,349,000$-2,248,000$-2,414,000$-3,164,000$-2,089,000
    EBIT$-5,014,000$-1,377,000$-1,184,000$-881,500$-7,345,000$-5,565,000$-3,564,000$-1,352,000$-2,252,000$-2,416,000$-3,170,000$-2,096,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PRFX

    News

    PRF Technologies raises $10M, advances clinical programs

    PRF Technologies secured $10 million through an equity line facility and reported significant progress in its clinical programs and renewable energy division. The company's subsidiary, LayerBio Inc., is preparing for a Phase 2 clinical trial for OcuRing-K, while preclinical results for PRF-110 showed sustained analgesic activity. Additionally, its DeepSolar division expanded its platform and joined the NVIDIA Connect program.

    Investing.com•7/27/26•
    Neutral

    PRF Technologies (Nasdaq: PRFX) details $10M raise, trials and AI energy

    PRF Technologies (Nasdaq: PRFX) announced a $10 million capital raise through an equity line facility, significantly strengthening its balance sheet for growth in biotechnology and AI-driven energy. Its biotech subsidiary, LayerBio, is preparing for a Phase 2 clinical trial for OcuRing™, and PRF-110 showed sustained analgesic activity. Concurrently, its DeepSolar and GridFeed energy platforms advanced with real-world data validation, new intelligence features, and participation in the NVIDIA Connect program.

    Stock Titan•7/27/26•
    Bullish

    PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

    PRF Technologies (NASDAQ: PRFX) has issued a letter to shareholders detailing its strengthened financial position, including a $10 million capital raise. The company is advancing its biotechnology efforts with LayerBio's preparations for a Phase 2 clinical trial of OcuRing™-K and expanded preclinical results for PRF-110. Concurrently, its DeepSolar AI-driven energy platform is moving towards commercial launch, validating Predict™ and joining the NVIDIA Connect program.

    Yahoo! Finance Canada•7/27/26•
    Bullish

    PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

    PRF Technologies (Nasdaq: PRFX) has issued a letter to shareholders detailing a strengthened financial position and significant progress across its biotechnology and AI-driven energy platforms. The company raised $10 million in new capital, is preparing for the Phase 2 clinical trial of OcuRing™-K, and DeepSolar is advancing towards commercial launch. Interim CEO Efraim Cohen-Arazi highlighted these achievements and outlined strategic priorities for continued growth and shareholder value creation.

    GlobeNewswire•7/27/26•
    Neutral

    PRF Technologies Ltd. Revenue Breakdown – NASDAQ:PRFX

    The article provides a basic overview of PRF Technologies Ltd. (NASDAQ: PRFX) financial information available on TradingView. It appears to be a stub or a landing page from a financial data platform, offering sections for financial statements, statistics, dividends, earnings, and segment performance data. The content primarily lists navigation options and different data categories related to the company.

    TradingView•7/25/26•
    Neutral

    Frequently Asked Questions About PRFX

    Does PRFX pay dividends?
    Painreform Ltd (PRFX) does not currently pay a regular dividend.
    What is PRFX's market cap?
    Painreform Ltd (PRFX) has a market capitalization of $2.92M with a current stock price of $0.95.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In